AtaGenix Laboratories
AtaGenix Laboratories
Struggling with monoclonal antibody development? AtaGenix offers phage display custom services to streamline the process and deliver high-quality antibodies in less than 2 months. Our solutions address challenges like immunogenicity and complex humanization by providing direct access to human monoclonal antibodies. With the world’s first immune phage display library derived from human cancer patient donors and diverse naïve libraries featuring Fab, scFv, and VHH formats, we ensure unmatched diversity and efficiency.
AtaGenix guarantees at least three high-affinity binders tailored for applications such as ELISA, WB, or Flow Cytometry. Backed by extensive expertise and a proven track record, we are leaders in therapeutic, research, and diagnostic antibody development. Partner with us for innovative solutions and accelerated project success.
Rapid Turnaround
Get your antibodies in <2 months
Binding Guaranteed
At least 3 high-affinity binders
Proven Expertise
Benefit from our vast experience with over 500 successful phage display projects
A streamlined antibody development workflow, from immune library construction to functional validation. Designed for high diversity, precise screening, and rigorous testing, ensuring stable and effective antibody candidates for research, therapy, or diagnostics.
Milestone: Library diversity > 10⁹
Milestone: Selection of cross-reactive binders
Milestone: Stable and active antibody candidates
Milestone: Identification of lead candidates
A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.
This article explores a 2022 peer-reviewed study published in The Journal of Immunology, revealing that Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) in Litopenaeus vannamei (shrimp) acts as a conserved anti-inflammatory factor. The research demonstrates that extracellular MANF suppresses ERK phosphorylation and downregulates Dorsal (NF-κB) via a receptor-type tyrosine phosphatase (RPTP) in hemocytes, highlighting an ancient immune regulation mechanism with implications for neuroprotection, metabolism, and aging. Cross-species validation in human 293T cells further confirms MANF’s conserved role. Supported by AtaGenix, the study utilized advanced techniques including plasma proteomics, qPCR, and sandwich ELISA with phage display-generated monoclonal antibodies. This breakthrough, detailed as of August 24, 2025, underscores AtaGenix’s role in accelerating innate immunity research through custom antibody discovery, protein expression, and assay development.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
